Evidence map›Paper›PMID 34226685›Full record

ReviewBritish journal of cancer2021

Biological basis for novel mesothelioma therapies.

Joanna Obacz, Henry Yung, Marie Shamseddin, Emily Linnane, Xiewen Liu, Arsalan A Azad, Doris M Rassl, David Fairen-Jimenez, Robert C Rintoul, Marko Z Nikolić and 1 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Prognostic Value of EMT Gene Signature in Malignant Mesothelioma.International journal of molecular sciences · 2023
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Joanna ObaczCambridge Institute for Medical Research, Keith Peters Building, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-4539-9946
Henry YungUCL Respiratory, Division of Medicine Rayne Institute, University College London, London, UK.
Marie ShamseddinWellcome Sanger Institute, Wellcome Trust Genome Campus, Saffron Walden, UK.
Emily LinnaneAdsorption & Advanced Materials Laboratory, Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Xiewen LiuAdsorption & Advanced Materials Laboratory, Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Arsalan A AzadCambridge Institute for Medical Research, Keith Peters Building, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
Doris M RasslDepartment of Histopathology, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
David Fairen-JimenezAdsorption & Advanced Materials Laboratory, Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-5013-1194
Robert C RintoulDepartment of Oncology, University of Cambridge, Cambridge, UK.
Marko Z NikolićUCL Respiratory, Division of Medicine Rayne Institute, University College London, London, UK.ORCID http://orcid.org/0000-0001-6304-6848
Stefan J MarciniakCambridge Institute for Medical Research, Keith Peters Building, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK. sjm20@cam.ac.uk.ORCID http://orcid.org/0000-0001-8472-7183
University of Cambridge · GBUniversity College London · GBPapworth Hospital NHS Foundation Trust · GBWellcome Sanger Institute · GB

Funding

Medical Research Council G1002610Medical Research Council MR/R009120/1Medical Research Council MR/S005579/1Medical Research Council MR/V028669/1
6 · The paper itself

Abstract

Mesothelioma is an aggressive cancer that is associated with exposure to asbestos. Although asbestos is banned in several countries, including the UK, an epidemic of mesothelioma is predicted to affect middle-income countries during this century owing to their heavy consumption of asbestos. The prognosis for patients with mesothelioma is poor, reflecting a failure of conventional chemotherapy that has ultimately resulted from an inadequate understanding of its biology. However, recent work has revolutionised the study of mesothelioma, identifying genetic and pathophysiological vulnerabilities, including the loss of tumour suppressors, epigenetic dysregulation and susceptibility to nutrient stress. We discuss how this knowledge, combined with advances in immunotherapy, is enabling the development of novel targeted therapies.

Indexed as

Gene Regulatory NetworksAsbestosCombined Modality TherapyEpigenesis, GeneticHumansMesotheliomaPrognosisAsbestos

Identifiers

PMID34226685
PMCPMC8505556
OpenAlexW3182664105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.